# Fulgent Genetics share price today (Fulgent Genetics, Inc., FLGT)

> Fulgent Genetics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. FLGT · Healthcare · Diagnostics & Research · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/flgt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $19.37 (−13.7% in a year)
- P/E: 8.6× (higher than 96% of the last 1 year)
- Revenue (Jun 2026): $85.4 M (+4.4% on a year ago)
- Profit (Jun 2026): −$29.7 M
- Operating margin: −39.4% (−15.3 points on a year ago)
- ROE: −6%, FY25
- ROIC: −15.1%, against a 9.2% cost of capital: −24.3 points
- Profit that came in as cash: 122%, last 2 years

Biggest thing to watch: the P/E is higher than 96% of its own history, so the multiple has already done part of the work. ## What is the Fulgent Genetics share price today? Fulgent Genetics, Inc.'s share price was $19.37 at the close on 3 November 2026. It has been stalling near its high for 8 weeks. That is 0.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $30, and at that close it sat 33% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 10 years the share price moved +110% while the S&P 500 moved +249%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Fulgent Genetics pay? Fulgent Genetics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Fulgent Genetics on? Fulgent Genetics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Fulgent Genetics profitable? Fulgent Genetics, Inc. posted a net loss of $29.7 M in the Jun 2026 quarter. The full FY25 year was a loss of $61.6 M. That loss is 34.8% of the quarter's revenue. The same quarter a year earlier lost $19.3 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Fulgent Genetics make, and is it growing? Fulgent Genetics, Inc. reported $85.4 M of revenue in the Jun 2026 quarter, +4.4% on the same quarter a year earlier. Over 4 years it has grown −24.5% a year on average. The last full year, FY25, came in at $323 M. The last four reported quarters add to $324 M. FY25 revenue was $323 M, +13.8% on the year before. Recent pace: the last four quarters grew +6.9% on average, against −24.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.8%, against +5.6% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Fulgent Genetics keep? Fulgent Genetics, Inc.'s operating margin was −39.4% in the Jun 2026 quarter, 15.3 percentage points lower than the same quarter a year ago. Across 5 years it has been between −27.6% and 68.1%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −15.3 percentage points on the year while gross margin changed −12.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Fulgent Genetics' profit turning into cash? Over the last 2 years, 122% of Fulgent Genetics, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 its operations used $102 M of cash, against −$61.6 M of profit. After $22.6 M of spending on assets, free cash was −$124 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Fulgent Genetics' cash go? Fulgent Genetics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $85.1 M on assets over the last 3 years. Averaged over those years that is 8.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $85.1 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Fulgent Genetics' P/E ratio, and how does it compare with its own history? Fulgent Genetics, Inc.'s P/E is 8.6×, near the high end of its own history: higher than 96% of past readings. Its usual P/E (the middle reading) is 4.6×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Fulgent Genetics business getting better or worse? Fulgent Genetics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Fulgent Genetics earn on its capital? Fulgent Genetics, Inc. earned a ROE of −6% in FY25. That is up from a low of −16% in FY23. Its return on capital used (ROIC) is 24.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −19.1% net margin and 0.27× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −19.1% net margin × 0.27× asset turnover × 1.10× leverage (assets divided by equity) ≈ −5.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −15.1% − 9.2% = −24.3 percentage points. The 9.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −15.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −10.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Fulgent Genetics have too much debt? Fulgent Genetics, Inc. has total debt of $9.6 M against shareholder equity of $996 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Fulgent Genetics shareholding pattern? 12.8% of Fulgent Genetics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Fulgent Genetics from balance-sheet trouble? For Fulgent Genetics, Inc., the Z-score is 5.15. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.15 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Fulgent Genetics rank in its industry? There is no score against its industry: Fulgent Genetics, Inc. is not among the largest members shown in this industry comparison for Diagnostics & Research. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Fulgent Genetics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Fulgent Genetics in size? Fulgent Genetics is the 32nd largest of 34 Diagnostics & Research companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Personalis, Inc., OPKO Health, Inc., Castle Biosciences, Inc. and Myriad Genetics, Inc. Just below it: Biodesix, Inc. and Exagen Inc. ### Diagnostics & Research companies close in size

1. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) $1.7 billion
2. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) $1.3 billion
3. [Castle Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/cstl) $1.1 billion
4. [Myriad Genetics, Inc.](https://www.sectoralpha.in/us/stocks/mygn) $578 million
5. Fulgent Genetics, Inc. $533 million
6. [Biodesix, Inc.](https://www.sectoralpha.in/us/stocks/bdsx) $222 million
7. [Exagen Inc.](https://www.sectoralpha.in/us/stocks/xgn) $202 million

[All 34 Diagnostics & Research companies, largest first](https://www.sectoralpha.in/us/sectors/diagnostics-research#all-companies)

### Companies close in size in other industries

1. [Krispy Kreme, Inc.](https://www.sectoralpha.in/us/stocks/dnut) $568 million · Grocery Stores
2. [Park Aerospace Corp.](https://www.sectoralpha.in/us/stocks/pke) $568 million · Aerospace & Defense
3. Fulgent Genetics, Inc. $567 million
4. [LightPath Technologies, Inc.](https://www.sectoralpha.in/us/stocks/lpth) $567 million · Electronic Components
5. [MiMedx Group, Inc.](https://www.sectoralpha.in/us/stocks/mdxg) $566 million · Biotechnology

## What else do people ask about Fulgent Genetics? ### What were Fulgent Genetics's latest quarterly results? Fulgent Genetics, Inc. reported revenue of $85.4 M and a net loss of $29.7 M for the Jun 2026 quarter. Earnings per share were −$1.05. The operating margin was −39.4%, 15.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Fulgent Genetics's market cap? Fulgent Genetics, Inc.'s market capitalisation is $533 M at a stock price of $19.37. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Fulgent Genetics performing? Fulgent Genetics, Inc.'s share price has been stalling near its high for 8 weeks. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Fulgent Genetics's stock price go up? This page does not forecast Fulgent Genetics, Inc.'s stock price. What it shows instead: the stock price is $19.37, and it has been stalling near its high for 8 weeks. Its P/E of 8.6× is higher than 96% of its own last 1 years (as of 3 November 2026). ### Where is Fulgent Genetics in its business cycle? Fulgent Genetics, Inc.'s FY25 operating margin was −27.6%, against a 5-year range of −27.6% to 68.1%: the low end of its own range, which is often where recoveries start. The latest quarter was −39.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Fulgent Genetics story? Biggest thing to watch: the P/E is higher than 96% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Fulgent Genetics a stock worth studying right now? What the numbers show: Fulgent Genetics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.